Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of ($0.19), $0.15 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $69.3 million versus the consensus estimate of $70.24 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.